Is conservative surgery a good option for patients with "triple negative" breast cancer?

The Breast : Official Journal of the European Society of Mastology
David Martinez-RamosJ L Salvador-Sanchis

Abstract

Triple negative breast cancers (negative estrogen receptor, progestagen receptor and no overexpression of HER2) seems to be more aggressive than other breast carcinoma subtypes. Therefore, it is necessary to analyze if a more aggressive surgical treatment should be offered to this subgroup of patients. The Castellon Cancer Registry Database (C.Valenciana, Spain) was used to identify eligible breast cancer patients. Female patients who were diagnosed and/or treated from January 2000 to December 2008 with primary, invasive, unilateral breast cancer at our hospital were included. A total of 410 patients make up the study population. Kaplan-Meier curves and log-rank tests were used to estimate 5-year local recurrence functions and to compare them across strata. Cox proportional hazards models were used to calculate hazard ratios and 95% confidence intervals to fit the effect of conservative surgery and other independent variables on local recurrence. Median follow-up time was 60 months (1-127 months). A total of 21 patients (5%) presented a local recurrence during follow-up. There was a 9% difference in terms of local recurrence between conservative and non-conservative techniques for triple negative patients, whereas such differen...Continue Reading

References

Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce G HafftyDeborah Toppmeyer
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul L NguyenJay R Harris
Aug 5, 2008·International Journal of Radiation Oncology, Biology, Physics·Rahul R ParikhBruce G Haffty
Nov 15, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·William J Irvin, Lisa A Carey
Dec 17, 2008·Archives of Gynecology and Obstetrics·Mar MuñozJosé Schneider
Aug 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dezheng HuoOlufunmilayo I Olopade
Sep 25, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S J DawsonC Caldas
Nov 11, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O GluzN Harbeck
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K David VoducHagen Kennecke
Apr 13, 2010·The Breast : Official Journal of the European Society of Mastology·Catherine OakmanAngelo Di Leo
Nov 12, 2010·Journal of Cancer Research and Clinical Oncology·Tim C de RuijterVivianne C Tjan-Heijnen
Mar 29, 2011·Annals of Surgical Oncology·Sandra S ZakyJerome C Landry

❮ Previous
Next ❯

Citations

May 7, 2013·Expert Opinion on Drug Discovery·Martiniano BelloJosé Correa-Basurto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.